Results 101 to 110 of about 656,371 (370)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease

Haematologica, 2012
The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate.
Francesco Mannelli, Giacomo Gianfaldoni, Tamara Intermesoli, Chiara Cattaneo, Erika Borlenghi, Sergio Cortelazzo, Irene Cavattoni, Enrico Maria Pogliani, Monica Fumagalli, Emanuele Angelucci, Claudio Romani, Fabio Ciceri, Consuelo Corti, Anna Scattolin, Agostino Cortelezzi, Daniele Mattei, Ernesta Audisio, Orietta Spinelli, Elena Oldani, Alberto Bosi, Alessandro Rambaldi, Renato Bassan   +21 more
doaj   +1 more source

Minimal residual disease and circulating tumor cells in breast cancer [PDF]

, 2011
Tumor cell dissemination in bone marrow or other organs is thought to represent an important step in the metastatic process. The detection of bone marrow disseminated tumor cells is associated with worse outcome in early breast cancer.
A Markou, A Vincent-Salomon, A Zippelius, AC Wolff, AG Tibbe, AH Talasaz, AM Sieuwerts, AM Sieuwerts, American Joint Committee on Cancer, B Aktas, B Mostert, B Rack, BK Zehentner, C Alix-Panabieres, CA Klein, CA Klein, D Barkan, DA Smirnov, DJ McBride, E Borgen, E Borgen, E Munzone, EA Punnoose, EI Galanzha, EP Diamandis, FC Bidard, G Deng, G Kallergi, G Wiedswang, GN Naumov, GT Budd, H Schwarzenbach, H Schwarzenbach, I Van der Auwera, J Ferlay, J Kraan, J Lu, JA Guirre-Ghiso, JA Schardt, JD Farrar, JS de Bono, JY Pierga, JY Pierga, K Hunter, K Pachmann, K Pantel, L Harris, LM Flores, M Al-Hajj, M Balic, M Cristofanilli, M Ignatiadis, M Ignatiadis, M Pestrin, M Tewes, MC Liu, Michail Ignatiadis, MJ Slade, MM Heiss, MM Reinholz, Monica Reinholz, MT Sandri, N Krawczyk, N Xenidis, O Schmidt-Kittler, P De Cremoux, P Wulfing, PR Gascoyne, R Aft, RE Board, RJ Cote, RT Krivacic, S Almokadem, S Braun, S Braun, S Krishnamurthy, S Maheswaran, S Meng, S Meng, S Nagrath, S Riethdorf, S Riethdorf, S Riethdorf, S Zheng, SJ Cohen, SJ Tan, SL Stott, T Brabletz, T Fehm, T Fehm, T Fehm, TG Ntouroupi, TJ Molloy, U De Giorgi, V Bozionellou, V Choesmel, V Zieglschmid, W Janni, WJ Allard, Y Hu, Y Husemann, Y Jiang   +101 more
core   +2 more sources

Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia [PDF]

arXiv, 2023
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced ...
arxiv  

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia

Advanced Medical Journal
Background and ObjectiveThe detection of minimal residual disease at the end of initial therapy in Acute Lymphoblastic Leukemia to assess risk stratification is gaining clinical significance.
Fatima Hameed Ahmad, Adnan Anwer Al-Doski   +1 more
doaj   +1 more source

The potential for liquid biopsies in the precision medical treatment of breast cancer. [PDF]

, 2016
Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2), based on primary tumor biology.
Barrak, Dany K, Elhodaky, Mostafa, Forte, Victoria A, Lang, Julie E, Snow, Anson, Tung, Lily   +5 more
core   +1 more source

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Journal of Clinical Oncology, 2019
PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia.
A. Kater, J. Seymour, P. Hillmen, B. Eichhorst, A. Langerak, C. Owen, M. Verdugo, J. Wu, E. Punnoose, Yanwen Jiang, Jue Wang, M. Boyer, K. Humphrey, M. Mobasher, T. Kipps   +14 more
semanticscholar   +1 more source

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Cytometry. Part B, Clinical cytometry, 2020
Flow‐cytometric minimal residual disease (FC‐MRD) monitoring is a well‐established risk‐stratification factor in B‐lymphoblastic leukemia/lymphoma (‐B‐ALL) and is being considered as a basis for deintensification or escalation in treatment protocols ...
P. Tembhare, Papagudi G Subramanian Pg, S. Ghogale, G. Chatterjee, N. Patkar, Avinash Gupta, Rahul Shukla, Y. Badrinath, N. Deshpande, G. Narula, Pearl Rodrigues, K. Girase, D. Dhaliwal, M. Prasad, D. Shetty, S. Banavali, S. Gujral   +16 more
semanticscholar   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source